A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.

ABSTRACT: In a phase I clinical trial, one hundred healthy young adults were randomized to receive two doses 28 days apart of an inactivated, subvirion vaccine containing 15 or 45microg of influenza A/H5N1 hemagglutinin (HA) by the intramuscular (IM) route, or 3 or 9microg of H5 HA by the intradermal(ID) route. Seventy-seven subjects received a third dose. All regimens were safe and well tolerated. Antibody responses after two or three doses were low (

SUBMITTER: Patel SM 

PROVIDER: S-EPMC2913582 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature